An Overview:
In the dynamic realm of healthcare innovation, the convergence of pharmaceuticals and medical devices has led to the development of groundbreaking combination products. However, ensuring the safety and efficacy of these products requires navigating a complex regulatory landscape. For those seeking to introduce drug-device combination products to the European market, obtaining a Notified Body (NB) opinion is a crucial step.
In this blog post, we’ll explore the process flow for acquiring a European NB opinion for drug device combination products and the key considerations at each stage.
You can also check our service page on the drug-device combination products for more details.
Looking for a Medical Device Regulatory Consultant?
Let’s have a word about your next project
Understanding the Regulatory Context
Before diving into the specifics of the process, it’s essential to understand the regulatory context governing drug-device combination products in Europe. These products are subject to both the Medical Device Regulation (MDR) and the Medicinal Products Regulation (MPR), which necessitate adherence to stringent standards for safety, efficacy, and quality.
Initial Assessment and Classification
The journey begins with a comprehensive initial assessment to determine the classification of the combination product. Factors such as its primary mode of action, intended use, and associated risks play a crucial role in classification. This step sets the stage for identifying the applicable regulatory requirements and the level of scrutiny during the evaluation process.
Design and Development
Once the product is classified, the design and development phase ensues. Collaboration between pharmaceutical and medical device experts is essential to ensure the seamless integration of drug and device components. Rigorous design controls and quality management systems are employed to uphold safety, efficacy, and quality standards throughout the development process.
Compilation of Technical Documentation
Central to the regulatory submission is the compilation of comprehensive technical documentation. This dossier should encompass all relevant data on device design, pharmaceutical formulation, manufacturing processes, risk management, and clinical evidence. Ensuring the completeness and accuracy of this documentation is paramount to facilitate a thorough evaluation by the NB.
Submission to Notified Body
With the technical documentation finalized, the submission is made to a designated Notified Body. Notified Bodies are independent organizations authorized by EU member states to assess the conformity of medical devices and combination products with regulatory requirements. The submission initiates the evaluation process, where experienced assessors meticulously review the documentation.
Evaluation and Assessment
During the evaluation phase, the Notified Body assesses the submitted documentation to verify compliance with regulatory requirements and standards. This involves scrutinizing all aspects of the product, including design, manufacturing processes, risk management measures, and clinical data. Any deficiencies or gaps identified during the evaluation must be addressed promptly to progress through the approval process.
Issuance of NB Opinion
Upon successful completion of the evaluation process, the Notified Body issues its opinion regarding the conformity of the combination product with regulatory requirements. This opinion serves as a pivotal milestone, indicating that the product meets the necessary standards for market approval within the EU. It provides assurance to regulators, healthcare professionals, and patients regarding the safety and performance of the product.
Conclusion
Navigating the process for obtaining a European NB opinion for drug-device combination products requires meticulous planning, interdisciplinary collaboration, and adherence to stringent regulatory requirements. By understanding the process flow outlined above and addressing key considerations at each stage, developers can streamline the approval process and bring innovative therapies to patients in need. Despite the challenges posed by the regulatory landscape, obtaining a European NB opinion represents a significant milestone on the path to market access and ultimately improving patient outcomes.
Secure Your European Notified Body Opinion With Operon Strategist’s Expert Guidance.
Operon Strategist's Expertise in Drug-Device Combination Product Regulation
Operon Strategist specializes in guiding clients through the intricate regulatory landscape surrounding drug-device combination products. Our dedicated team of experts is committed to providing comprehensive support, from initial assessment to securing a European Notified Body (NB) opinion. Ready to streamline your path to market approval? Contact Operon Strategist today and unlock success in bringing your innovative combination product to patients in need. Let’s navigate the regulatory maze together and pave the way for success!
